Security Benefit Life Insurance Company’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Security Benefit Life Insurance Company’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.56K	Hold	150,000	–	–	﹤0.01%	19
2026 Q1	$1.88K	Hold	150,000	–	–	﹤0.01%	19
2025 Q4	$4.08K	Hold	150,000	–	–	﹤0.01%	19
2025 Q3	$5.28K	Hold	150,000	–	–	﹤0.01%	18
2025 Q2	$5.71K	Hold	150,000	–	–	﹤0.01%	18
2025 Q1	$10.5K	Hold	150,000	–	–	﹤0.01%	16
2024 Q4	$5.04K	Hold	150,000	–	–	﹤0.01%	20
2024 Q3	$4.72K	Buy	+150,000	New	+$8.69K	﹤0.01%	21

Other funds holding SLXNW

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

DCM

Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Security Benefit Life Insurance Company's SLXNW Position: Q2 2026 in Review

Security Benefit Life Insurance Company held its Silexion Therapeutics Warrant (SLXNW) position steady in Q2 2026 at 150,000 shares worth $4.56K. The position accounts for ﹤0.01% of the portfolio, ranked #19.

Security Benefit Life Insurance Company first reported a position in SLXNW in Q3 2024 and has held it in 8 quarters since. The position peaked at $10.5K in Q1 2025. 3 funds tracked by Wall St. Rank hold SLXNW as of Q2 2026.

Security Benefit Life Insurance Company held 150,000 shares of Silexion Therapeutics Warrant worth $4.56K as of Q2 2026.
Security Benefit Life Insurance Company left its Silexion Therapeutics Warrant share count unchanged in Q2 2026.
Silexion Therapeutics Warrant made up ﹤0.01% of Security Benefit Life Insurance Company's portfolio in Q2 2026, its #19 holding.
Security Benefit Life Insurance Company first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 8 quarters since.
Security Benefit Life Insurance Company's Silexion Therapeutics Warrant position peaked at $10.5K in Q1 2025.
3 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2026.

Based on Security Benefit Life Insurance Company's 13F filing for Q2 2026, filed 21 Jul 2026.